• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过临床靶向二代测序鉴定的平滑肌肉瘤中的突变谱。

Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.

作者信息

Lee Paul J, Yoo Naomi S, Hagemann Ian S, Pfeifer John D, Cottrell Catherine E, Abel Haley J, Duncavage Eric J

机构信息

Department of Pathology and Immunology, Washington University, St. Louis, MO, United States.

Department of Genetics, Washington University, St. Louis, MO, United States.

出版信息

Exp Mol Pathol. 2017 Feb;102(1):156-161. doi: 10.1016/j.yexmp.2017.01.012. Epub 2017 Jan 14.

DOI:10.1016/j.yexmp.2017.01.012
PMID:28093192
Abstract

Recurrent genomic mutations in uterine and non-uterine leiomyosarcomas have not been well established. Using a next generation sequencing (NGS) panel of common cancer-associated genes, 25 leiomyosarcomas arising from multiple sites were examined to explore genetic alterations, including single nucleotide variants (SNV), small insertions/deletions (indels), and copy number alterations (CNA). Sequencing showed 86 non-synonymous, coding region somatic variants within 151 gene targets in 21 cases, with a mean of 4.1 variants per case; 4 cases had no putative mutations in the panel of genes assayed. The most frequently altered genes were TP53 (36%), ATM and ATRX (16%), and EGFR and RB1 (12%). CNA were identified in 85% of cases, with the most frequent copy number losses observed in chromosomes 10 and 13 including PTEN and RB1; the most frequent gains were seen in chromosomes 7 and 17. Our data show that deletions in canonical cancer-related genes are common in leiomyosarcomas. Further, the spectrum of gene mutations observed shows that defects in DNA repair and chromosomal maintenance are central to the biology of leiomyosarcomas, and that activating mutations observed in other common cancer types are rare in leiomyosarcomas.

摘要

子宫和非子宫平滑肌肉瘤中反复出现的基因组突变尚未完全明确。利用一个包含常见癌症相关基因的二代测序(NGS)面板,对来自多个部位的25例平滑肌肉瘤进行检测,以探索基因改变,包括单核苷酸变异(SNV)、小插入/缺失(indels)和拷贝数改变(CNA)。测序显示,21例病例的151个基因靶点中有86个非同义编码区体细胞变异,平均每例有4.1个变异;4例在检测的基因面板中无假定突变。最常发生改变的基因是TP53(36%)、ATM和ATRX(16%),以及EGFR和RB1(12%)。85%的病例检测到CNA,10号和13号染色体上观察到最常见的拷贝数缺失,包括PTEN和RB1;7号和17号染色体上观察到最常见的拷贝数增加。我们的数据表明,在平滑肌肉瘤中,经典癌症相关基因的缺失很常见。此外,观察到的基因突变谱表明,DNA修复和染色体维持缺陷是平滑肌肉瘤生物学特性的核心,而在其他常见癌症类型中观察到的激活突变在平滑肌肉瘤中很少见。

相似文献

1
Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.通过临床靶向二代测序鉴定的平滑肌肉瘤中的突变谱。
Exp Mol Pathol. 2017 Feb;102(1):156-161. doi: 10.1016/j.yexmp.2017.01.012. Epub 2017 Jan 14.
2
The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.应用 DNA 和 RNA 测序对子宫肌瘤和子宫平滑肌肉瘤的鉴别诊断。
Am J Obstet Gynecol. 2019 Oct;221(4):320.e1-320.e23. doi: 10.1016/j.ajog.2019.05.018. Epub 2019 May 20.
3
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.子宫平滑肌肉瘤的外显子测序鉴定出TP53、ATRX和MED12的常见突变。
PLoS Genet. 2016 Feb 18;12(2):e1005850. doi: 10.1371/journal.pgen.1005850. eCollection 2016 Feb.
4
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.新一代测序揭示叶状肿瘤中频繁出现的MED12突变及可采取行动的治疗靶点。
Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.
5
Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.通过MSK-IMPACT对种系变异进行全面检测,MSK-IMPACT是一种用于实体瘤分子肿瘤学和并发癌症易感性检测的临床诊断平台。
BMC Med Genomics. 2017 May 19;10(1):33. doi: 10.1186/s12920-017-0271-4.
6
Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.靶向外显子组测序分析平滑肌肉瘤中的基因改变。
Genes Chromosomes Cancer. 2016 Feb;55(2):124-30. doi: 10.1002/gcc.22318. Epub 2015 Nov 6.
7
Targeted exome sequencing and chromosomal microarray for the molecular diagnosis of nevoid basal cell carcinoma syndrome.靶向外显子组测序和染色体微阵列分析用于痣样基底细胞癌综合征的分子诊断
J Dermatol Sci. 2017 Jun;86(3):206-211. doi: 10.1016/j.jdermsci.2017.02.282. Epub 2017 Mar 11.
8
Two novel variants in the ATM gene causing ataxia-telangiectasia, including a duplication of 90 kb: Utility of targeted next-generation sequencing in detection of copy number variation.ATM基因中的两个导致共济失调毛细血管扩张症的新型变异,包括一个90 kb的重复:靶向新一代测序在检测拷贝数变异中的应用
Ann Hum Genet. 2019 Jul;83(4):266-273. doi: 10.1111/ahg.12312. Epub 2019 Mar 19.
9
The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations.Li-Fraumeni 综合征和种系视网膜母细胞瘤突变对平滑肌肉瘤发生、结局的影响,以及基因检测推荐。
Clin Cancer Res. 2024 Oct 15;30(20):4780-4790. doi: 10.1158/1078-0432.CCR-24-1160.
10
Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.采用下一代测序技术对软组织肉瘤进行分子谱分析:迈向精准治疗的初步研究。
Hum Pathol. 2014 Aug;45(8):1563-71. doi: 10.1016/j.humpath.2014.04.012. Epub 2014 Apr 24.

引用本文的文献

1
Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine.平滑肌肉瘤的分子异质性及其对个体化医学的影响。
Curr Treat Options Oncol. 2024 May;25(5):644-658. doi: 10.1007/s11864-024-01204-5. Epub 2024 Apr 24.
2
The Future of Targeted Therapy for Leiomyosarcoma.平滑肌肉瘤靶向治疗的未来
Cancers (Basel). 2024 Feb 26;16(5):938. doi: 10.3390/cancers16050938.
3
Paraneoplastic movement disorder due to suspected metastatic Leiomyosarcoma of tongue: A case report.疑似舌部转移性平滑肌肉瘤所致副肿瘤性运动障碍:一例报告
Clin Case Rep. 2024 Mar 7;12(3):e8648. doi: 10.1002/ccr3.8648. eCollection 2024 Mar.
4
mutation in aggressive uterine adenosarcoma in which systemic chemotherapies had remarkable effects.侵袭性子宫腺肉瘤中的突变,其中全身化疗有显著效果。
Int Cancer Conf J. 2023 Jan 12;12(2):120-125. doi: 10.1007/s13691-022-00591-6. eCollection 2023 Apr.
5
Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients.平滑肌肉瘤中循环肿瘤DNA基因改变的鉴定:73例患者的分子分析
J Immunother Precis Oncol. 2020 Jun 5;3(2):64-68. doi: 10.36401/JIPO-20-3. eCollection 2020 May.
6
Genomic Characterization of Rare Primary Cardiac Sarcoma Entities.罕见原发性心脏肉瘤实体的基因组特征分析
Diagnostics (Basel). 2023 Jan 6;13(2):214. doi: 10.3390/diagnostics13020214.
7
Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review.子宫平滑肌肉瘤的分子见解:系统评价。
Int J Mol Sci. 2022 Aug 27;23(17):9728. doi: 10.3390/ijms23179728.
8
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.提高软组织肉瘤免疫治疗疗效:一种基于生物标志物和组织类型的综述。
Front Immunol. 2021 Dec 3;12:775761. doi: 10.3389/fimmu.2021.775761. eCollection 2021.
9
ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.ATRX改变促进多形性肉瘤的肿瘤生长和免疫逃逸。
Cancers (Basel). 2021 Apr 29;13(9):2151. doi: 10.3390/cancers13092151.
10
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).平滑肌肉瘤患者未满足的医疗需求及未来展望——来自国家平滑肌肉瘤基金会(NLMSF)和欧洲肉瘤患者网络(SPAEN)的立场文件
Cancers (Basel). 2021 Feb 20;13(4):886. doi: 10.3390/cancers13040886.